Immediate Impact
92 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
2024 Standout
Works of Anne E. Borgman-Hagey being referenced
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Anne E. Borgman-Hagey | 96 | 35 | 22 | 48 | 7 | 117 | |
| Terri Goldberg | 59 | 31 | 30 | 32 | 11 | 98 | |
| Yamil Alonso Lopez Chuken | 74 | 28 | 17 | 28 | 5 | 90 | |
| Erik Ramon‐Gil | 69 | 49 | 24 | 34 | 5 | 120 | |
| Magdalena Żotkiewicz | 80 | 60 | 29 | 37 | 6 | 137 | |
| Aibing Xu | 82 | 72 | 36 | 40 | 10 | 175 | |
| Derek-Zhen Xu | 118 | 88 | 26 | 45 | 6 | 162 | |
| Katsumi Terashita | 74 | 54 | 22 | 31 | 8 | 182 | |
| Jiali Chen | 83 | 54 | 58 | 22 | 10 | 185 | |
| Joseph Hreiki | 58 | 70 | 19 | 21 | 6 | 147 | |
| Ann‐Shing Lee | 87 | 23 | 23 | 15 | 7 | 115 |
All Works
Loading papers...